DB15802InvestigationalVaccines
AV-COVID-19 is a vaccine composed of autologous dendritic cells loaded with SARS-CoV-2 antigens and with or without Granulocyte-macrophage colony-stimulating factor (GM-CSF). The vaccine is created from the receiving patients’ isolated... The monocytes are then differentiated in vitro into dendritic cells with IL-4 and GM-CSF, incubated with SARS-CoV-2 antigens prior to administration.
- Also known as
- DC-ATA · DCV
- Code names
- AV-COVID-19
What you can answer from here — as of April 02, 2025
Which companies are running trials of AV-COVID-19, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account